The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer

  • Authors:
    • Asahiro Morishita
    • Jian Gong
    • Takako Nomura
    • Hirohito Yoshida
    • Kunihiko Izuishi
    • Yasuyuki Suzuki
    • Yoshio Kushida
    • Reiji Haba
    • Jeanine D'Armiento
    • Tsutomu Masaki
  • View Affiliations

  • Published online on: October 1, 2010     https://doi.org/10.3892/ijo_00000733
  • Pages: 829-835
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Several studies have reported that activated receptor tyrosine kinases (RTKs) are highly expressed in colon cancer and may promote tumor growth and survival. However, there is little information available as to the function and signaling of RTKs in colon cancers. In the present study, we performed protein array technology to determine the expression status of various RTKs that are activated in colon cancer compared to normal colonic cells and tissues. Of the 42 different phospho-RTKs, 5 (ErbB2, FGFR1, FGFR2a, FGFR3 and MSPR) were activated in Caco-2, SW480, WiDr, Lovo colon cancer cell lines and cancerous tissues. In order to determine the effect of inhibition of RTKs, especially ErbB2, athymic nude mice bearing xenograft tumors were treated with the ErbB2-targeting drug trastuzumab alone, or in combination with 5-Fluorouracil (5-FU). Similar to the treatment of 5-FU alone, trastuzumab suppressed the growth of colon cancer. Combination therapy of trastuzumab and 5-FU inhibited tumor growth significantly compared to the treatment of 5-FU alone or trastuzumab alone. In addition, xenograft tumors were also analyzed by phospho-MAPK protein array. The activity of Akt3/PKBγ was inhibited with 5-FU alone and trastuzumab, indicating that trastuzumab may inhibit colon cancer growth through ErbB2-Akt3/PKBγ signaling. These data demonstrate that ErbB2 could be an important candidate for colon cancer therapy and the addition of trastuzumab to 5-FU therapy might augment the clinical response in colon cancer patients. Therefore, the analysis of phospho-RTK expression by protein array as a useful tool might identify novel therapies for individual patients with colon cancer.

Related Articles

Journal Cover

October 2010
Volume 37 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Morishita A, Gong J, Nomura T, Yoshida H, Izuishi K, Suzuki Y, Kushida Y, Haba R, D'Armiento J, Masaki T, Masaki T, et al: The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol 37: 829-835, 2010.
APA
Morishita, A., Gong, J., Nomura, T., Yoshida, H., Izuishi, K., Suzuki, Y. ... Masaki, T. (2010). The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. International Journal of Oncology, 37, 829-835. https://doi.org/10.3892/ijo_00000733
MLA
Morishita, A., Gong, J., Nomura, T., Yoshida, H., Izuishi, K., Suzuki, Y., Kushida, Y., Haba, R., D'Armiento, J., Masaki, T."The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer". International Journal of Oncology 37.4 (2010): 829-835.
Chicago
Morishita, A., Gong, J., Nomura, T., Yoshida, H., Izuishi, K., Suzuki, Y., Kushida, Y., Haba, R., D'Armiento, J., Masaki, T."The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer". International Journal of Oncology 37, no. 4 (2010): 829-835. https://doi.org/10.3892/ijo_00000733